Table 5.
Comparison of previous reports concerning c.309T>G and lung cancer prognosis
| Author | Year | Country | Ethnic group | Smoker (%) | Stage | Histology | Subgroup | N | MDM2 c.309T>G SNP309 | HR | 95% CI | P | Correlation | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heist | 2007 | States | Caucasian | 93% | Stage I, II | NSCLC | 383 | T//T vs. G/G | 1.57 | 1.03–2.40 | 0.04 | G/G risk | 15 | |
| AC | 186 | T/T vs. G/G | 0.93 | 0.48–1.80 | 0.82 | NS | ||||||||
| SQ | 110 | T/T vs. G/G | 3.77 | 1.88–7.57 | 0.0002 | G/G risk | ||||||||
| Stage IA | 200 | T/T vs. G/G | 0.65 | 0.33–1.27 | 0.2 | NS | ||||||||
| Stage IB or II | 183 | T/T vs. G/G | 3.19 | 1.80–5.65 | <0.0001 | G/G risk | ||||||||
| Noncurrent smoker | 233 | T/T vs. G/G | 1.17 | 0.66–2.08 | 0.58 | NS | ||||||||
| Current smoker | 150 | T/T vs. G/G | 2.93 | 1.52–5.67 | 0.001 | G/G risk | ||||||||
| Han | 2008 | Korea | Asian | 75% | Stage IIIB or IV | NSCLC | 148 | T/T vs. T/G + G/G | 1.74 | 1.05–2.89 | 0.032 | T/G + G/G risk | 16 | |
| Chua | 2010 | Singapore | Asian | 0% | Lung cancer | 123 | T/T vs. T/G vs. G/G | NA | 0.27(log‐rank) | N.S. | 18 | |||
| Chien | 2010 | Taiwan | Asian | 51% | Stage I‐III | NSCLC | 198 | T/T vs. G/G | 0.62 | 0.41–0.95 | 0.003 | T/T risk | 17 | |
| Stage I | 127 | T/T vs. G/G | 0.47 | 0.22–1.01 | 0.05 | NS | ||||||||
| Stage I with wild‐type p53 | 99 | T/T vs. G/G | 0.34 | 0.15–0.80 | 0.01 | T/T risk | ||||||||
| Stage I with p53 mutation | 28 | T/T vs. G/G | 5.02 | 0.31–28.20 | 0.35 | NS | ||||||||
| Stage II, III | 179 | T/T vs. G/G | 0.82 | 0.48–1.39 | 0.45 | NS | ||||||||
| Liu | 2011 | China | Asian | 59% | Stage III or IV | NSCLC | 199 | T/T vs. G/G | 1.05 | 0.66–1.67 | 0.91(log‐rank) | NS | 19 | |
| Dong | 2011 | China | Asian | 72% | Stage I‐IV | NSCLC | 561 | G/G vs. T/T + T/G | 1.37 | 1.06–1.78 | 0.017 | T/T + T/G risk | 20 | |
| Ryan | 2012 | States | Caucasian and African‐American | 92% | Stage I‐IV | NSCLC | 197 | T/T vs. G/G | 0.8 | 0.51–1.24 | 0.31 | NS | 12 | |
| This study | 2015 | Japan | Asian | 45% | Stage I | AC | 179 | T/G + G/G vs. T/T | 2.23 | 1.07–4.65 | 0.033 | T/T risk |
HR, hazard ratio; CI, confidence interval; Ref., Reference; NSCLC, non‐small‐cell lung cancer; NS, not significant; NA, not available; AC, adenocarcinoma; SQ, squamous cell carcinoma.